使用二肽基肽酶-4抑制剂降低骨折风险：是否存在不朽时间偏倚？ - Suppr

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?

作者信息

Driessen J H M, Knapen L M, Geusens P P M M, van den Bergh J P W

机构信息

CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.

NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.

出版信息

Osteoporos Int. 2017 Aug;28(8):2429-2430. doi: 10.1007/s00198-017-4120-2. Epub 2017 Jul 13.

DOI:10.1007/s00198-017-4120-2

PMID:28707090

Abstract

摘要

相似文献

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?

Osteoporos Int. 2017 Aug;28(8):2429-2430. doi: 10.1007/s00198-017-4120-2. Epub 2017 Jul 13.

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: response to Driessen et al.

Osteoporos Int. 2017 Aug;28(8):2431. doi: 10.1007/s00198-017-4139-4. Epub 2017 Jul 13.

Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia.

Ann Intern Med. 2016 Aug 16;165(4):JC20. doi: 10.7326/ACPJC-2016-165-4-020.

Dipeptidyl peptidases and related proteins: multifaceted markers and therapeutic targets.

Clin Chem Lab Med. 2009;47(3):245-7. doi: 10.1515/CCLM.2009.085.

Dipeptidyl Peptidase-4 Inhibitors and Beta Cell Mass in Japanese Adults with Type 2 Diabetes.

Endocr Pract. 2022 May;28(5):563-564. doi: 10.1016/j.eprac.2022.02.001. Epub 2022 Feb 7.

Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor.

CMAJ. 2022 May 24;194(20):E705. doi: 10.1503/cmaj.211933.

Pathophysiological Implications of Dipeptidyl Peptidases.

Curr Protein Pept Sci. 2017;18(8):843-849. doi: 10.2174/1389203718666170329104936.

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure.

Circulation. 2019 Jan 15;139(3):362-365. doi: 10.1161/CIRCULATIONAHA.118.038399.

Commentary on 'Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors'.

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):e439-e440. doi: 10.1111/jdv.14965. Epub 2018 May 3.

Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.

Bioorg Med Chem. 2011 Aug 15;19(16):4953-70. doi: 10.1016/j.bmc.2011.06.059. Epub 2011 Jun 28.

引用本文的文献

Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.

Osteoporos Int. 2019 Oct;30(10):1923-1940. doi: 10.1007/s00198-019-04968-x. Epub 2019 May 27.

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: response to Driessen et al.

Osteoporos Int. 2017 Aug;28(8):2431. doi: 10.1007/s00198-017-4139-4. Epub 2017 Jul 13.

本文引用的文献

Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.

Osteoporos Int. 2017 Aug;28(8):2421-2428. doi: 10.1007/s00198-017-4051-y. Epub 2017 Apr 29.

Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.

Diabetes Obes Metab. 2017 Mar;19(3):421-428. doi: 10.1111/dom.12843. Epub 2017 Jan 19.

DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes - A systematic review and meta-analysis.

Diabetes Res Clin Pract. 2016 Jun;116:288-98. doi: 10.1016/j.diabres.2016.04.029. Epub 2016 Apr 30.

Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial.

Diabetes Care. 2015 Nov;38(11):2142-50. doi: 10.2337/dc15-1068. Epub 2015 Sep 10.

Immortal time bias in observational studies of drug effects.

Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):241-9. doi: 10.1002/pds.1357.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?

作者信息

Driessen J H M, Knapen L M, Geusens P P M M, van den Bergh J P W

机构信息

CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.

NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.

出版信息

Osteoporos Int. 2017 Aug;28(8):2429-2430. doi: 10.1007/s00198-017-4120-2. Epub 2017 Jul 13.

DOI:10.1007/s00198-017-4120-2

PMID:28707090

Abstract

摘要

相似文献

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?

Osteoporos Int. 2017 Aug;28(8):2429-2430. doi: 10.1007/s00198-017-4120-2. Epub 2017 Jul 13.

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: response to Driessen et al.

Osteoporos Int. 2017 Aug;28(8):2431. doi: 10.1007/s00198-017-4139-4. Epub 2017 Jul 13.

Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia.

Ann Intern Med. 2016 Aug 16;165(4):JC20. doi: 10.7326/ACPJC-2016-165-4-020.

Dipeptidyl peptidases and related proteins: multifaceted markers and therapeutic targets.

Clin Chem Lab Med. 2009;47(3):245-7. doi: 10.1515/CCLM.2009.085.

Dipeptidyl Peptidase-4 Inhibitors and Beta Cell Mass in Japanese Adults with Type 2 Diabetes.

Endocr Pract. 2022 May;28(5):563-564. doi: 10.1016/j.eprac.2022.02.001. Epub 2022 Feb 7.

Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor.

CMAJ. 2022 May 24;194(20):E705. doi: 10.1503/cmaj.211933.

Pathophysiological Implications of Dipeptidyl Peptidases.

Curr Protein Pept Sci. 2017;18(8):843-849. doi: 10.2174/1389203718666170329104936.

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure.

Circulation. 2019 Jan 15;139(3):362-365. doi: 10.1161/CIRCULATIONAHA.118.038399.

Commentary on 'Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors'.

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):e439-e440. doi: 10.1111/jdv.14965. Epub 2018 May 3.

Bioorg Med Chem. 2011 Aug 15;19(16):4953-70. doi: 10.1016/j.bmc.2011.06.059. Epub 2011 Jun 28.

引用本文的文献

Osteoporos Int. 2019 Oct;30(10):1923-1940. doi: 10.1007/s00198-019-04968-x. Epub 2019 May 27.

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: response to Driessen et al.

Osteoporos Int. 2017 Aug;28(8):2431. doi: 10.1007/s00198-017-4139-4. Epub 2017 Jul 13.

本文引用的文献

Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.

Osteoporos Int. 2017 Aug;28(8):2421-2428. doi: 10.1007/s00198-017-4051-y. Epub 2017 Apr 29.

Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.

Diabetes Obes Metab. 2017 Mar;19(3):421-428. doi: 10.1111/dom.12843. Epub 2017 Jan 19.

DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes - A systematic review and meta-analysis.

Diabetes Res Clin Pract. 2016 Jun;116:288-98. doi: 10.1016/j.diabres.2016.04.029. Epub 2016 Apr 30.

Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial.

Diabetes Care. 2015 Nov;38(11):2142-50. doi: 10.2337/dc15-1068. Epub 2015 Sep 10.

Immortal time bias in observational studies of drug effects.

Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):241-9. doi: 10.1002/pds.1357.

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献